Since the opening of the HudsonAlpha Institute of Biotechnology in 2008, associate companies have been developing new diagnostics, therapeutics, healthcare products and offering a variety of services in the life sciences. The latest addition to the biotech campus, MetaboloStasis Therapeutics, has those same goals in mind, improving human health one disease at a time.
MetaboloStasis was established this year with the mission to develop therapeutics to treat individuals suffering from metabolic diseases, such as diabetes and copper disorders, and give them that missing stability, or homeostasis, hence the name MetaboloStasis.
President and founder, Tracy Nevitt, Ph.D., comes to HudsonAlpha from the University of Missouri where she was an Assistant Professor of Biochemistry. While working in academia, it was difficult for Nevitt to find a way to translate newly found knowledge into solutions that will extend patient lives, and starting MetaboloStasis gives her the opportunity to do so.
“What has driven me all along since I was 16 was to come up with a possible cure for disease,” said Nevitt. “I want to be able to translate that knowledge into therapeutics and get it to those patients in need.”
Now that Nevitt has established a presence on the HudsonAlpha campus, she is able to fill the gap between physicians and scientists. “It’s a complex interaction and a complex transition that I think would be a lot harder for me to do as a faculty member,” Nevitt said. “And now, I can do that here at HudsonAlpha.”
“We are pleased that MetaboloStasis is now one of the associate companies at HudsonAlpha,” said Carter Wells, Vice President for Economic Development. “Dr. Nevitt is driven to find answers for patients suffering from metabolic diseases and disorders. Our hope is that her work benefits from the collaborative environment created at HudsonAlpha.”
Nevitt plans to collaborate with HudsonAlpha faculty investigators and other associate companies and, in doing so, become a part of a community of life science organizations and entrepreneurs who convert science into market-ready health solutions.
“I’ve got my foot in the door, and I’m going to burst through it!” Nevitt said. “I hope that MetaboloStasis can be successful, give back to the community and most importantly, make a difference for patients.”
About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological challenges. Founded in 2008, its mission is four-fold: sparking scientific discoveries that can impact human health and well-being; bringing genomic medicine into clinical care; fostering biotech entrepreneurship; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus encourage collaborations that produce advances in medicine and agriculture. Under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education, and includes 29 diverse biotech companies on campus. To learn more about HudsonAlpha, visit: http://hudsonalpha.org/.
HudsonAlpha Media Contact: